Irbesartan perindopril combined treatment of chronic congestive heart failure efficacy.docVIP

 PAGE \* MERGEFORMAT 3 Irbesartan perindopril combined treatment of chronic congestive heart failure efficacy [Abstract] Objective To study the effects of perindopril and irbesartan in combination treatment of chronic congestive heart failure in the safety and effectiveness. Method of chronic heart failure were randomly divided into treatment group (48 cases) and control group (48 cases), on the basis of conventional therapy in heart failure treatment group received perindopril 2 ~ 8mg / d irbesartan 37.5 ~ 150mg / d, control group received perindopril 2 ~ 8mg / d. Observed 24 weeks after treatment were compared in patients with cardiac function to improve the situation, 6-minute walk distance, echocardiographic indicators of changes in serum potassium, urea nitrogen, creatinine, and changes in heart rate, blood pressure changes. Results after 24 weeks, Group 6-minute walking distance before and after treatment, left atrial diameter (LA), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), short - -axis shortening (FS), cardiac output (CO), cardiac index (CI) difference was statistically significant (t = 2.55,2.04,2.98,3.39,2.58,3.24,3.07,3.28 control group, respectively, t treatment groups, respectively = 2.35,2.14,3.08,3.29,2.56,3.22,3.05,3.18, P all amp;quot;0.05). After treatment between the two groups 6 minutes walking distance, LVEDV, LVESV, EF, FS difference was statistically significant (t = = 2.88,2.20,3.04,2.75,3.19, P all amp;quot;0.05); cardiac function improved significantly between the two groups statistically significant difference in efficiency (χ 2 = 4.85, P amp;lt;0.05); group before and after treatment serum potassium, urea nitrogen, creatinine difference was not statistically significant (t control group = 3.41,4.22,3.86, t the treatment group were = 3.46,4.38,3.89, P are amp;quot;0.05). Conclusion of perindopril and irbesartan combined treatment of chronic